A case of thrombocytopenia associated with the use of hydroxychloroquine following open heart surgery

Deniz Demir a,*, Fatih Ӧcal b, Mustafa Abanoz a, Hasan Dermenci b

a Şanlıurfa Mehmet Akif İnan State Hospital, Cardiovascular Surgery Department, Şanlıurfa, Turkey
b Şanlıurfa Mehmet Akif İnan State Hospital, Hematology Department, Şanlıurfa, Turkey

A R T I C L E   I N F O

Article history:
Received 21 August 2014
Received in revised form 10 November 2014
Accepted 10 November 2014
Available online 20 November 2014

Keywords:
Hydroxychloroquine
Cardiac surgery
Thrombocytopenia

A B S T R A C T

INTRODUCTION: Thrombocytopenia is a common problem occurring in patients and drug-induced thrombocytopenia is a significant cause of thrombocytopenia.

PRESENTATION OF CASE: We present an unusual case of thrombocytopenia that was considered to be associated with the use of hydroxychloroquine in the late term following open heart surgery.

DISCUSSION: The drug-induced thrombocytopenia, mechanical destruction of the platelets, and hemodilution are common causes of low platelet count. Although drug-induced immune thrombocytopenia has a mild clinical course in most cases (in this case it has severe clinical course), some patients may experience life-threatening hemorrhages. The decision to discontinue the drug that is deemed to be responsible from the drug-induced thrombocytopenia (DITP) relies on the clinical condition of the patient. The diagnosis is mostly established by discontinuation, exclusion, and correlation because the tests performed to detect drug-dependent antibodies (DDAbs) for the diagnosis of DITP are time-consuming, and these tests are also not commonly available. The authors of the current study diagnosed DITP by discontinuation of the drug. We suggest that the use of hydroxychloroquine could be severe thrombocytopenia occurring after open heart surgery.

CONCLUSION: The medication history must be carefully reviewed in patients presenting with thrombocytopenia, and if the medications could cause thrombocytopenia must be discontinued.

© 2014 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).

1. Introduction

Thrombocytopenia is a common problem occurring in patients hospitalized in cardiology and cardiac surgery units. Platelet count decreases below 100 × 109 cells/L in 2.4–9.2% of the patients who were placed on abxiximab, clopidogrel, or acetylsalicylic acid therapy after percutaneous coronary interventions.1 There is a risk of developing thrombocytopenia in 35–65% of the patients who undergo cardiac surgery.2

The idiopathic thrombocytopenic purpura, drug-induced thrombocytopenia, infections (rubella), and pseudo-thrombocytopenia are among the causes of thrombocytopenia.3

The current report presents a case of thrombocytopenia that was considered to be associated with the use of hydroxychloroquine in the late term following open heart surgery.

2. Presentation of case

A 55-year-old male patient underwent open heart surgery due to coronary artery disease that remained unresponsive to medical therapies. The patient was discharged from the hospital with full recovery one week after coronary artery bypass graft surgery. The platelet count at discharge after the operation was 308 × 109 cells/L. The patient was admitted to the outpatient clinics in the Department of Cardiovascular Surgery complaining of nose bleeding, petechiae on the body, and ecchymosis approximately three weeks after surgery (Fig. 1). The laboratory test revealed a platelet count of 7 × 109 cells/L, after which the patient consulted with a hematologist. The peripheral blood smear revealed an insufficient number of platelets and the absence of atypical cells, and the patient was then placed on steroid therapy with the pre-diagnosis of immune thrombocytopenia. The patient underwent bone marrow aspiration biopsy. The bone marrow aspiration biopsy was inconclusive with the exception of slightly increased megakaryocytes. During the follow-up of the patient, platelet count remained at low levels and did not respond to steroid therapy. The patient’s medical history was rechecked, and it was revealed that the patient had been using hydroxychloroquine for the last one week erroneously as a pain killer, unbeknownst to the surgeons; hydroxychloroquine use was...
discontinued. The platelet counts increased over a period of several days, and petechia and ecchymosis on the body disappeared. The platelet count at 1 month control visit was $300 \times 10^9$ cells/L. The patient is under follow up for 3 months and who was healthy in that time.

3. Discussion

The drug-induced thrombocytopenia, mechanical destruction of the platelets, and hemodilution are common causes of low platelet count encountered after open heart surgery.\(^1\)

Although drug-induced immune thrombocytopenia has a mild clinical course in most cases, in this case it was severe may depend of cross-reaction between acetyl salicylic acid and hydroxychloroquine. Many drugs can induce the development of immune thrombocytopenia such as antibiotics, antiinflammatories and anti-inflammatory drugs. However, the most common type of drug-induced thrombocytopenia is heparin-induced thrombocytopenia.\(^4\)

Treatment varies depending on the causes of thrombocytopenia. For instance, steroids and intravenous immunoglobulin (IVIG) therapy are used in the treatment of immune thrombocytopenic purpura, whereas direct thrombin inhibitors (bivalirudin, argatroban, lepirudin) are used in the treatment of heparin-induced thrombocytopenia.\(^5\,\,^6\)

Drug-induced thrombocytopenia occurs as a non-immune-mediated suppression of bone marrow or immune-mediated destruction of the platelets by specific antibodies to the drug. Thrombocytopenia is caused by myelosuppressive substances are dose-dependent and not difficult to recognize. However, immune-mediated thrombocytopenia is not dose-dependent and the diagnosis is challenging; the reason is that these patients use multiple medications.\(^7\)

The decision to discontinue the drug that is deemed to be responsible from the drug-induced thrombocytopenia (DITP) relies on the clinical condition of the patient. The diagnosis is mostly established by discontinuation, exclusion, and correlation because the tests performed to detect drug-dependent antibodies (DDAbs) for the diagnosis of DITP are time-consuming, and these tests are also not commonly available.\(^4\,\,^7\)

Transfusions and steroid therapy have been used in the treatment of DITP; however, there is no evidence on the efficiency of these therapies. The drug is eliminated from the body in a couple days in hospitalized patients, and this is followed by gradual increase in the platelet count. Thrombocytopenia and bleeding symptoms rarely persist for weeks. The patients with persistent symptoms can be administered therapies such as IVIG and plasma exchange therapy; however, the efficiency of these therapies has not been clearly demonstrated.\(^4\)

Hydroxychloroquine is used in the treatment of malaria, rheumatic disorders, and systemic lupus erythematosus.\(^8\) Many side effects have been reported associated with the use of hydroxychloroquine. Among these side effects, there is a particular concern regarding the development of cardiomyopathy and thrombocytopenia.\(^3\,\,^10\)

The patient was discharged with full recovery after open heart surgery. However, the patient was re-admitted at postoperative 3 weeks complaining of nose bleeding, petechiae, and ecchymosis on the body. The platelet count was very low upon admission. The peripheral blood smear revealed a low platelet count and the absence of atypical cells. The patient was deemed to have immune thrombocytopenia, for which he was placed on steroid therapy. However, the patient did not respond to therapy. Meanwhile, a more comprehensive medical history was obtained. It was revealed that the patient had been using hydroxychloroquine as a pain killer outside the knowledge of the surgeons. Hydroxychloroquine use was discontinued, and platelet count showed a gradual increase in the following days. The platelet count was $300 \times 10^9$ cells/L at the 1 month control visit. The patient is still under follow-up at 3 months without exhibiting any hemorrhage and other problems.

Before the patient presenting thrombocytopenia, who was using 100 mg acetyl salicylic acid, antibiotic and anti-inflammatory drug. During in this period, the patient’s platelet count was within normal range. However, after one week, severe thrombocytopenia was observed in the patient due to erroneously using hydroxychloroquine. In several days, after cessation of the drug platelet levels in the patient has become the normal range. Thrombocytopenia was observed while the patient was using acetylsalicylic acid and hydroxychloroquine. Both drugs can cause this case.\(^1\,\,^10\) The diagnosis was established by discontinuation and exclusion of hydroxychloroquine. After hydroxychloroquine was ceased, the patient became health. But who still using acetylsalicylic acid 100 mg and thrombocytopenia was not seen in controls. Therefore acetylsalicylic acid was not considered as a cause of thrombocytopenia in this patient. Also role of 100 mg acetyl salicylic in this case was considered as increasing of thrombocytopenia severity. In order to determination drug-dependent thrombocytopenia, mostly drug cessation and exclusion methods are used.\(^7\) Also in this case, drug cessation was used as exclusion method. We believe that the use of hydroxychloroquine is cause of thrombocytopenia.

4. Conclusion

The medication history must be carefully assessed in the differential diagnosis of patients presenting with isolated thrombocytopenia, and the drugs that might be possibly related to thrombocytopenia must be discontinued.

---

**Fig. 1.** Images showing petechiae on the chest of the patient.
Conflict of interest

Each author certifies that he has no commercial associations that might pose a conflict of interest in connection with the submitted article.

Funding

No funding support.

Ethical approval

Written informed consent was obtained from the patient for publication of this case report and accompanying images.

Author contributions

Dr. Deniz Demir Operation surgeon 1 and correspondence. Dr. Fatih Ocal Haematologist and review of literature. Dr. Mustafa Abanoz operation surgeon 2. Dr. Hasan Dermenci Haematologist and review of literature.

References

1. Matthai Jr WH. Thrombocytopenia in cardiovascular patients: diagnosis and management. Chest 2005;127(2):46–52.
2. Rezende E, Morais G, Silva Junior JM, Oliveira AM, Souza JM, Toledo DO, et al. Thrombocytopenia in cardiac surgery: diagnostic and prognostic importance. Rev Bras Cir Cardiovasc 2011;26(1):47–53.
3. Ashoub A, Lakshmanan S, Luckraz H. Cardiac surgery in a patient with severe thrombocytopenia: how low is too low? Ann CARD Anaesth 2013;16(3):215–7.
4. Aster RH, Curtis BR, McFarland JG, Bougie DW. Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management. J Thromb Haemost 2009;7(6):911–8.
5. LugaãœRdos S, Motta MP, de Azevedo MF, de Lima RG, AbrantesFde A, Abdala E, et al. Immune thrombocytopenic purpura induced by intestinal tuberculosis in a liver transplant recipient. World J Gastroenterol 2014;20(25):8304–8.
6. Velagic V, Samardzíc J, Baricevic Z, Skoric B, Cikes M, Gasparovic H, et al. Management of heparin-induced thrombocytopenia with fondaparinux in a patient with left ventricular assist device. Int J Organ Transplant Med 2014;5(2):83–6.
7. Bansal R, Sharma PK, Sharma A. A case of thrombocytopenia caused by rifampicin and pyrazinamide. Indian J Pharmacol 2013;45(4):405–7.
8. Cohen PR. Hydroxychloroquine associated hyperpigmentation mimicking elder abuse. Dermatol Ther (Heidelb) 2013;3(2):203–10.
9. Abbasi S, Tarfer L, Farzaneh-Far R, Farzaneh-Far A. Hydroxychloroquine: a treatable cause of cardiomyopathy. J Am Coll Cardiol 2012;60(8):786.
10. Nieweg HO, Bouma HG, Devries K, Jansz A. Haematological side-effects of some anti-rheumatic drugs. Ann Rheum Dis 1963;22:440–3.